Keywords: USA, AMA, Cannabinoid-based medicines, R&D, annaabais Science

AMA praised for urging USA to facilitate clinical R&D of cannabinoid-based medicines

Article | 24 November 2009

Cannabis Science, an emerging US pharmaceutical cannabis company, is hailing the call by the American Medical Association's House of Delegates for “marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical R&D of cannabinoid-based medicines."

Richard Cowan, Cannabis Science chief financial officer, noted: “The AMA has officially joined the other medical groups in their recognition of the medical value of cannabis. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in